Rion Engages Lonza To Scale Manufacturing Exosome Based Therapeutics

From LonzaSep 26 2025

RION, a commercialized and clinical-stage regenerative medicine institution pioneering platelet-derived exosomes for some quality and animal wellness applications, has announced a collaboration pinch Lonza, 1 of nan world’s largest statement improvement and manufacturing organizations (CDMOs), to supply cGMP manufacturing and method support for commercialized standard accumulation of its Purified Exosome Product™ (PEP™) supplier constituent for precocious shape objective proviso and beyond.

RION developed a proprietary biomanufacturing level enabling scaled accumulation of platelet-derived exosomes. This level allows for nan advancement of RION’s pipeline of exosome-based therapeutics crossed aggregate indications. Under nan position of nan agreement, Lonza will manufacture PEP™ drug constituent astatine its manufacturing installation successful Houston (US). RION will leverage Lonza’s world-leading, state-of-the-art extracellular vesicles expertise and capabilities to operationalize its process astatine scale.

PEP™ is an exosome-based therapeutic level campaigner pinch immunomodulatory, anti-inflammatory and insubstantial regenerative properties, formulated arsenic a shelf-stable lyophilized powder. Stabilized regenerative exosomes beforehand insubstantial repair and tin beryllium administered done aggregate routes, enabling usage crossed a wide group of indications. RION is advancing objective programs successful precocious insubstantial regeneration, immune-mediated dermatology diseases, musculoskeletal disease, pulmonary disease, cardiovascular wellness and women’s health.

This collaboration pinch Lonza ensures that our proprietary exosome manufacturing level tin beryllium scaled to meet objective and early commercialized demand. RION’s breakthrough successful exosome biomanufacturing now paired pinch Lonza’s world infrastructure allows america to bring this biologics-based invention to patients quickly and reliably, while staying existent to our ngo of affordable access."

Atta Behfar, Cofounder and CEO, RION

Davide Zocco, Commercial Development Head for Exosomes and mRNA Technologies, Specialized Modalities, Lonza, added: “We are pleased to support RION’s groundbreaking activity successful exosome-based therapies. Through our world-leading capabilities successful exosome development, characterization, and manufacturing, we alteration our customers to advancement their innovative therapies efficiently and reliably. Through our collaboration pinch RION, we will use our expertise to support nan manufacture of PEP™ drug substance, aiming to thief accelerate nan readiness of innovative treatments to patients worldwide.”